{"filings":[{"id":94497,"accession_number":"0001493152-26-019485","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["8.01","2.02","2.01","7.01","9.01"],"status":"ready","headline":"enVVeno receives FDA IDE approval for pivotal study of non-surgical venous valve; $25M cash","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA grants first-ever IDE for a U.S. pivotal study of a non-surgical replacement venous valve (enVVe System).","TAVVE study: stage 1 enrolls 10 patients; stage 2 enrolls 220 patients (165 valve, 55 control) at up to 40 US sites.","Company reports ~$25M cash/investments as of March 31, 2026, funding operations into Q3 2027.","Addresses ~3 million U.S. patients with severe deep CVI; no effective current treatments for valvular incompetence.","enVVe features: 13Fr delivery profile, porcine pericardium leaflet, no general anesthesia needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7391095.516838796,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106923,"accession_number":"0001493152-26-005030","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"enVVeno Medical regains Nasdaq minimum bid price compliance; reports $28M cash at year-end","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received formal Nasdaq notice confirming compliance with minimum bid price rule; closing bid ≥ $1.00 for 10 consecutive business days Jan 20 - Feb 2, 2026, matter closed.","Cash and investments balance approximately $28 million as of December 31, 2025.","Company expects to share additional details on 2026 strategic plans in coming weeks; believes it is well-positioned for 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7391095.516838796,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106922,"accession_number":"0001493152-26-002860","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"enVVeno Medical effects 1:35 reverse stock split, shares outstanding drop to ~655,606","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio 1:35 effective Jan 20, 2026; no fractional shares issued, rounded up.","Outstanding shares reduced from 22,946,223 to 655,606; authorized shares unchanged at 250M.","Proportional adjustments made to stock options and warrants (e.g., exercise price increased 35x).","Common stock began trading on split-adjusted basis Jan 20, 2026; transfer agent Equiniti managing exchange."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7391095.516838796,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123248,"accession_number":"0001493152-25-027482","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"enVVeno stockholders reject 2025 equity plan; authorize reverse stock split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Jenusaitis (3.47M for, 1.80M withheld) and Berman (4.73M for, 0.54M withheld) as Class II directors.","Advisory say-on-pay passed: 3.19M for, 1.96M against, 5.79M broker non-votes.","Stockholders voted AGAINST the 2025 Equity Incentive Plan (2.48M for, 2.62M against); 2016 plan remains.","Approved reverse stock split authorization (7.31M for, 1.58M against) at ratio of 1:5 to 1:35 at Board discretion.","Ratified CBIZ CPAs P.C. as auditor for FY2025 (10.86M for, 0.14M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7391095.516838796,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123247,"accession_number":"0001493152-25-024494","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"enVVeno Medical lowers stockholder meeting quorum to 33-1/3% voting power","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved amendment to Section 1.5 of Amended and Restated Bylaws on November 17, 2025.","New quorum threshold: presence of holders of 33⅓% of voting power of outstanding shares entitled to vote.","Amendment effective immediately upon Board approval; no stockholder vote required.","Change modifies quorum requirement from the prior standard (not specified) to one-third threshold."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7391095.516838796,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123246,"accession_number":"0001493152-25-022440","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"enVVeno loses FDA appeal for VenoValve PMA; shifts focus to enVVe device","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Unfavorable FDA appeal upheld not-approvable letter for VenoValve (received Aug 19, 2025).","Company to redirect resources to next-gen transcatheter valve enVVe, ready for human testing.","Cash and investments totaled $31.5M at Q3 end; quarterly burn $4-5M funds operations into 2027.","No approved treatments exist for severe deep CVI from valvular incompetence, affecting up to 3.5M US patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7391095.516838796,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123245,"accession_number":"0001493152-25-020276","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"enVVeno Medical enters ATM offering agreement for up to $50M of common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Ladenburg Thalmann allows sale of up to $50M of common stock from time to time.","Shares sold at market prices; agent receives 3% commission on gross proceeds.","ATM shares issued under existing effective S-3 registration statement (filed Aug 23, 2023).","Company has no obligation to sell shares; may suspend or terminate the program at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7391095.516838796,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123244,"accession_number":"0001493152-25-017691","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2025-10-10T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"enVVeno Medical receives Nasdaq bid-price deficiency notice; cure period to April 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified enVVeno on Oct 7, 2025 that bid price closed below $1.00 for 30 consecutive business days.","Company has until April 6, 2026 to regain compliance by closing at or above $1.00 for 10 consecutive trading days.","If unmet, may seek 180-day extension by meeting other listing standards and committing to reverse stock split.","No immediate effect on listing; stock remains on Nasdaq Capital Market pending cure or appeal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7391095.516838796,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139926,"accession_number":"0001493152-25-012181","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"enVVeno receives FDA not-approvable letter for VenoValve PMA","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA issued not-approvable letter for VenoValve PMA, citing insufficient benefit-risk profile.","FDA raised concerns about bias without hemodynamic measurement and safety from open surgical procedure.","Company reviewing options including resubmission or appeal; continues to work with FDA.","VenoValve is lead product for severe deep chronic venous insufficiency; no approved effective treatments currently.","Company also developing non-surgical enVVe valve; expects to apply learnings for its IDE application."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":7391095.516838796,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157527,"accession_number":"0001641172-25-011729","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"enVVeno Medical appoints Jennifer Bright as CFO, replacing Craig Glynn","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Craig Glynn resigned as CFO effective May 19, 2025; will serve as consultant for transition.","Jennifer Bright appointed CFO; 25+ yr CPA, ex-CFO of BIOLASE, salary $300K, bonus up to 40%.","Bright awarded 350,000 stock options at $3.62/share, vesting over 3 years with 1-year cliff.","No disagreement with Glynn; standard employment and indemnification agreements signed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7391095.516838796,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157526,"accession_number":"0001641172-25-005547","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"enVVeno Medical replaces auditor Marcum with CBIZ CPAs after acquisition of Marcum's attest business","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum resigned as auditor effective April 17, 2025; CBIZ CPAs engaged with Audit Committee approval.","No adverse opinions, disagreements, or reportable events in Marcum's reports for FY 2024 and 2023.","Change results from CBIZ's acquisition of Marcum's attest business on November 1, 2024.","Marcum provided a letter agreeing with the company's statements (Exhibit 16.1)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7391095.516838796,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192809,"accession_number":"0001493152-24-051926","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2024-12-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"enVVeno Medical reports annual meeting results; elects two directors, approves say-on-pay frequency","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Dr. Francis Duhay and Dr. Sanjay Shrivastava as Class I directors for three-year terms.","Approved non-binding advisory resolution on executive compensation: 3,255,160 for, 2,665,653 against, 5,299,752 broker non-votes.","Selected '1 year' as preferred frequency for future say-on-pay votes: 3,976,538 for 1 year.","Ratified Marcum LLP as independent auditor for FY 2024: 11,071,482 for, 233,605 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":7391095.516838796,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209238,"accession_number":"0001493152-24-038828","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2024-09-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"enVVeno Medical closes $15M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$15M from sale of 4,206,106 common shares and 79,609 pre-funded warrants at $3.50/$3.4999.","Underwriter (Titan Partners) granted 30-day option for up to 642,857 additional shares at the offering price.","Underwriter receives warrant for 300,001 shares at $4.025, exercisable starting 6 months post-closing for 5 years.","Offering conducted via prospectus supplement under effective shelf registration statement (File No. 333-273546)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7391095.516838796,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227171,"accession_number":"0001493152-24-015752","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2024-04-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"enVVeno: 72% of VenoValve patients show clinically meaningful benefit; FDA filing on track for Q4 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["72% of SAVVE trial patients achieved ≥3-point rVCSS improvement at a weighted average of 11 months post-surgery.","Overall average rVCSS improvement of 8.46 points for meaningful-benefit cohort; 9.29 points at two-year milestone.","94% of patients showed clinical improvement (≥1 point rVCSS) at a weighted average of 11 months post-implant.","Company expects to complete one-year data collection by September 2024 and file PMA for FDA approval in Q4 2024.","Cash and investments of $46.4M at Dec 31, 2023 expected to fund operations through FDA decision and end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7391095.516838796,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246060,"accession_number":"0001493152-24-008950","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2024-03-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"enVVeno Medical Reports Positive VenoValve Pivotal Trial Data; 97% of Patients Show Clinical Improvement at Six Months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["97% of VenoValve study patients showed clinical improvement at six months measured by revised Venous Clinical Severity Score (rVCSS).","74% of patients achieved clinically meaningful benefit (rVCSS improvement of 3 or more points).","Average rVCSS improvement per patient was 8 points, over 2.5 times the threshold for clinically meaningful benefit.","Company on track to file VenoValve FDA approval application (PMA) in Q4 2024.","Data presented at 2024 American Venous Forum Annual Meeting in Tampa, Florida on March 6, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":7391095.516838796,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263517,"accession_number":"0001493152-23-044010","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2023-12-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"enVVeno stockholders elect Robert C. Gray as Class III director, ratify Marcum LLP as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Robert C. Gray elected as Class III director for three-year term (5.48M votes for, 0.89M withheld, 2.78M broker non-votes).","Marcum LLP ratified as independent auditor for FY2023 (9.04M for, 87,979 against, 20,598 abstentions).","Annual meeting held December 5, 2023; 9,148,893 shares represented out of 13,316,636 entitled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":7391095.516838796,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263516,"accession_number":"0001493152-23-041594","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2023-11-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"enVVeno Medical reports positive preliminary safety data from VenoValve pivotal trial; 8% MAE rate, no deaths or PEs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary device-related MAE rate 8% for fully enrolled 75-patient SAVVE trial; no deaths or pulmonary embolisms.","Six DVTs occurred; three adjudicated as device-related mild, three pending, expected similar results.","Higher-than-expected procedure-related bleeding in contiguous sub-group, all moderate, attributed to anticoagulation.","Company expects to present topline efficacy data in Q2 2024 and file PMA application in Q4 2024.","enVVeno also developing enVVe transcatheter valve; pivotal trial expected to begin Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7391095.516838796,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263515,"accession_number":"0001493152-23-037065","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2023-10-12T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"enVVeno raises $28M in PIPE financing with milestone-based warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $28M from sale of 3,844,704 shares, pre-funded warrants for 977,900 shares, and two tranches of warrants.","Tranche A warrants (4,822,604 shares) at $6.945, expire 30 days post SAVVE top-line data or Oct 2024.","Tranche B warrants (4,822,604 shares) at $8.334, expire 30 days post FDA PMA for VenoValve or Oct 2026.","Net proceeds ~$25.9M; funds for VenoValve and enVVe development and working capital.","Ladenburg Thalmann placement agent; 7% cash fee and warrants for 241,130 shares at $6.945."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7391095.516838796,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337701,"accession_number":"0001493152-22-034589","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2022-12-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"enVVeno Medical shareholders elect Berman and Jenusaitis as Class II directors; ratify Marcum as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Robert A. Berman re-elected with 2,378,488 votes for, 697,978 withheld; 2,373,744 broker non-votes.","Matthew M. Jenusaitis re-elected with 1,869,004 votes for, 1,207,462 withheld; 2,373,744 broker non-votes.","Ratification of Marcum LLP as independent auditor for FY 2022 passed: 5,445,167 for, 4,108 against, 935 abstain.","Annual meeting held Nov 30, 2022; 5,450,210 of 9,471,932 entitled shares present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":7391095.516838796,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410218,"accession_number":"0001493152-21-030440","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K/A","filed_at":"2021-12-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"enVVeno files 8-K/A correcting shareholder vote tallies for annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Corrected vote counts show Dr. Francis Duhay received 3,420,358 votes for; Dr. Sanjay Shrivastava 3,342,772 votes for as Class I directors.","Shareholders ratified Marcum LLP as auditor with 6,085,415 votes for, 11,290 against.","Approved amendment increasing incentive plan shares to 4.5 million; 2,523,717 votes for, 1,254,579 against.","Approved evergreen provision requiring plan shares ≥20% of fully diluted shares; 2,504,985 votes for, 1,273,777 against.","No change to results of proposals; filing corrects clerical vote tabulation error."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":7391095.516838796,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410220,"accession_number":"0001493152-21-030154","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2021-12-01T23:59:59+00:00","items":["5.07","7.01"],"status":"ready","headline":"enVVeno expects 9 SAVVE trial sites active; shareholders approve director elections, plan amendments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Dr. Francis Duhay and Dr. Sanjay Shrivastava as Class I directors for terms ending at 2024 annual meeting.","Ratified Marcum LLP as independent auditor for FY2021 with 6,085,415 for, 11,290 against, 9,074 abstain.","Approved amendment to 2016 Omnibus Incentive Plan increasing authorized shares to 4,500,000 (2,458,617 for, 1,254,579 against).","Approved evergreen provision requiring at least 20% fully diluted shares under plan (2,439,885 for, 1,273,777 against).","By end of week, expects 9 sites active and enrolling in SAVVE U.S. pivotal trial for VenoValve."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7391095.516838796,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410219,"accession_number":"0001493152-21-024390","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2021-10-01T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Hancock Jaffe Laboratories renamed enVVeno Medical; new tickers NVNO and NVNOW","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name change effective 12:01 a.m. Eastern on October 1, 2021.","Certificate of Amendment filed with Delaware Secretary of State on September 29, 2021.","Common stock now trades as NVNO; warrants as NVNOW on Nasdaq.","Company had previously been known as Hancock Jaffe Laboratories, Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7391095.516838796,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":429055,"accession_number":"0001493152-21-023320","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2021-09-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Hancock Jaffe to rename enVVeno Medical, focus on venous disease; VenoValve trial to start","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name change to enVVeno Medical Corporation, tickers NVNO/NVNW effective Oct 1, 2021.","VenoValve SAVVE pivotal trial ready to enroll 75 patients at up to 20 U.S. centers.","Development of second venous disease product 'enVVe' initiated; expected unveil mid-2022.","CoreoGraft cardiac bypass program discontinued to focus on venous disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7391095.516838796,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":429054,"accession_number":"0001493152-21-022214","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2021-09-08T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Hancock Jaffe raises $20M in registered direct offering with Perceptive Advisors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $20M from sale of 781,615 shares at $7.872/share and pre-funded warrants for 1,759,035 shares at $0.0001 exercise.","Net proceeds approximately $18.2M after placement agent fees (8% cash fee plus warrants) and expenses.","Proceeds to be used for general corporate purposes and clinical development of the VenoValve.","Company prohibited from issuing common stock or equivalents for 50 days post-closing; variable rate transactions banned for 6 months.","Closing expected on or about September 9, 2021; Ladenburg Thalmann acting as exclusive placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7391095.516838796,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":429053,"accession_number":"0001493152-21-019562","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2021-08-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Hancock Jaffe enters $25M ATM equity offering with Ladenburg Thalmann","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $25M of common stock may be sold through Ladenburg Thalmann as agent.","Ladenburg Thalmann will receive a 3% commission on gross proceeds.","Agreement effective until August 12, 2023, or earlier termination.","Sales may be made at market prices on Nasdaq Capital Market or in negotiated transactions.","Company is not obligated to sell any shares under the agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7391095.516838796,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}